Here are the current drug injury litigations for which we are handling personal injury or wrongful death lawsuits.
Dupixent has been associated with an increased risk of T-cell lymphoma, cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), mycosis fungoides, and Sézary syndrome.
Ozempic, Wegovy, and Rybelsus have been associated with an increased risk of eye problems, including possible vision loss and blindness due to non-arteritic anterior ischemic optic neuropathy (NAION).
Zepbound and Mounjaro have been associated with an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), resulting in vision loss and blindness.
Ozempic, Wegovy, and Rybelsus have been associated with an increased risk of eye problems, including possible vision loss and blindness due to non-arteritic anterior ischemic optic neuropathy (NAION).
Andexxa has been associated with an increased risk of blood clots that can result in pulmonary embolism (PE) or deep vein thrombosis (DVT) requiring hospitalization.
Case Evaluation: Current Drug Injury Litigations
Free Drug Injury Case Evaluation page
- The prescription drugs discussed on this site are approved for use by the United States Food and Drug Administration (FDA).
- Patients should not stop taking any prescription drug without seeking the advice of their medical doctor.
- The prescription drug names are registered trademarks of the respective drug companies.
- This site is not affiliated with any of the drug companies or the FDA.